Firm will be able to conduct drug discovery and possibly development based on these molecules.

Alcon entered into a five-year research agreement with AstraZeneca, which gives it exclusive discovery and potential development rights to AstraZeneca’s compound library for ophthalmic conditions. The two companies are targeting development of drugs to treat sight-threatening conditions such as glaucoma, wet and dry age-related macular degeneration, ocular allergy, and dry eye.

Under the terms of the agreement, Alcon obtains multiple classes of small molecules, including already identified lead compounds. AstraZeneca will hand over development and regulatory documentation associated with each compound as relevant to ophthalmology. Alcon will perform and fund all research and development activities to move selected compounds forward.

The agreement also provides for individual license agreements to be negotiated on a case by case basis for any compound that moves into clinical development, including regulatory milestone payments and royalties on product sales.

Previous articleOpinion—Regulatory Planning Key for Emerging Technology Companies
Next articleNycomed’s Intranasal Fentanyl Drug Gains European Approval for Breakthrough Cancer Pain